Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of primary G-CSF prophylaxis with FOLFIRI + bevacizumab in UGT1A1*28 homozygous metastatic colorectal cancer
2007-001772-37Phase 2Completed
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Jun 2007
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenograstim, bevacizumab, irinotecan, folinic acid and fluorouracil in colorectal cancer (CRC), sponsored by Fédération Francophone de Cancérologie Digestive. Primary endpoint: Grade 4 or febrile neutropenia rate during treatment. Started Jun 2007; status: completed.
02
Drugs
lenograstimbevacizumabirinotecanfolinic acidfluorouracil
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2007-001772-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001772-37.